In the February issue of the ARCHIVES,1 we reported a case of Churg-Strauss syndrome (CSS) with prominent skin involvement that was successfully treated with a combination of low-dose interferon alfa-2a (Roferon-A), 9 × 106to 13 × 106 IU/wk, and prednisolone, 20 mg/d. The patient presented initially in April 1999 with a half-year history of recurrent bronchial infections and airway obstruction. He had no history of asthma or other allergic diseases. Four weeks before admission he was prescribed prednisolone, 10 mg, and a combination of fluticasone propionate and salmeterol xinafoate (Viani forte Discus) for inhalation. The interferon alfa therapy was well tolerated by the patient and all laboratory parameters and the eosinophil counts returned to values slightly above the normal range. However, when the interferon alfa dose was tapered below 9 × 106 IU/wk, the rash instantly reappeared within 1 week and the eosinophil counts increased. In August 1999 the patient had a bronchial infection with fever and rhinopharyngitis, which led to a strong increase of the eosinophil counts combined with eosinophilic pulmonary infiltration and rash, and the interferon alfa dose had to be increased to 18 × 106 IU/wk. In December 1999 we found a letter on the Food and Drug Administration homepage discussing a connection between CSS development and treatment with inhaled fluticasone (http://www.fda.gov/medwatch/safety/1999/floven.htm). This prompted us to substitute the fluticasone treatment with budesonide (Pulmicort). Pulmonary eruptions improved spontaneously, and there was a complete resolution of the vasculitic rash. All blood parameters including eosinophil counts returned to normal values within 4 weeks, enabling us to discontinue the interferon alfa therapy and to keep the patient on a regimen of 20 mg/d of prednisolone and inhalation of albuterol and budesonide for the treatment of his bronchitis. When the patient was seen 2 months later in February 2000 with another bronchial infection, the white blood cell counts showed a leukocytosis with elevated neutrophil counts, and eosinophil counts in the normal range. We consider this finding as strong evidence that the CSS was no longer active. The patient remained well without any symptoms of CSS or vasculitis during the year 2000 and is currently treated with 20 mg/d of prednisolone and inhaled budesonide, showing only minor airway obstruction and a peakflow of 300 to 400 mL/min.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.